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Abstract: The incidence of type 2 diabetes mellitus (T2DM) is increasing worldwide, and 
certain population subgroups are especially vulnerable to the disease. To reduce T2DM risk and 
progression at the population level, preventative strategies are needed that can be implemented on 
a population-wide scale with minimal cost and effort. Chronic low-grade inflammation resulting 
from oxidative stress and imbalances in the innate immune system has been associated with 
obesity, metabolic syndrome, and insulin resistance – critical stages in the development and 
progression of T2DM. Therefore, inflammation may play a causal role in the pathogenesis of 
T2DM, and reducing it via modulation of oxidative stress and the innate immune response could 
lead to a status of improved insulin sensitivity and delayed disease onset. Dietary supplementa-
tion with anti-inflammatory and antioxidant nutritional factors, such as micronutrients, might 
present a novel strategy toward the prevention and control of T2DM at the population level. 
This review examines current knowledge linking oxidation, inflammatory signaling pathways, 
and vitamin supplementation or intake to the risk of T2DM. The concept that micronutrients, 
via attenuation of inflammation, could be employed as a novel preventive measure for T2DM 
is evaluated in the context of its relevance to public health.
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Introduction
Type 2 diabetes mellitus (T2DM) has reached global epidemic proportions. The 
disease affects over 150 million people worldwide, a number that is expected to double 
by 2025.1 It is estimated that six people die every minute from T2DM globally, a figure 
that will soon make the disease one of the world’s most prevalent causes of prevent-
able mortality.2 Rates of disease incidence increase with age, obesity, and a sedentary 
lifestyle, are elevated in certain ethnicities (Hispanics, Africans, and Aboriginals), and 
have been increasingly noted in children.3,4
T2DM is a multifactorial disease characterized by chronic hyperglycemia, altered 
insulin secretion, and insulin resistance – a state of diminished responsiveness to 
normal concentrations of circulating insulin.5,6 T2DM is also defined by impaired 
glucose tolerance (IGT) that results from islet β-cell dysfunction, followed by insulin 
deficiency in skeletal muscle, liver, and adipose tissues.7,8 In individuals with IGT, 
the development of T2DM is governed by genetic predisposition and environmental 
variables (a hypercaloric diet and the consequent visceral obesity or increased adiposity 
in liver and muscle tissues) and host-related factors (age, imbalances in oxidative 
stress, and inflammatory responses)1,5,9–16 (Figure 1). Clinical complications of T2DM 
include both microvascular diseases (eg, retinopathy, nephropathy, and neuropathy) Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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Figure 1 interaction between genetic predisposition, environment, and host-related 
factors affecting T2DM and potential areas of focus for intervention. The development 
of T2DM results from the interaction between genetic predisposition, environmental 
exposures, and various host-related factors. single-nucleotide polymorphisms within 
several genes, such as TCF7L2, PPARG, and KCNJ11, have been associated with T2DM 
risk  via  candidate  gene  studies  and  genome-wide  associations.  Lack  of  physical 
activity and a hypercaloric diet, with the resulting visceral obesity and increased 
adiposity in liver and muscle tissue, are associated with T2DM risk as well. Finally, 
host-related factors such as age, oxidative stress, and chronic inflammation also 
play a role in the development of the disease. Therapeutic interventions aimed at 
modifying lifestyle and/or levels of oxidative stress and chronic inflammation may aid 
in T2DM prevention and control.
and macrovascular complications (eg, myocardial infarction, 
peripheral vascular disease, and stroke).5 The macrovascular 
diseases are considered to be the leading cause of mortality 
among diabetics.17
A significant body of evidence highlights the key role of 
abnormal innate immune responses and chronic low-grade 
inflammation in the pathogenesis of insulin resistance and 
the development of T2DM.9,18–20 Inflammation results from 
the activation of the innate immune response – the body’s 
immediate, nonspecific reaction against environmental 
insults such as pathogens and chemical or physical injury.9 
  Inflammation plays a role in prevention of tissue damage, 
restoration of tissue homeostasis, and destruction of infectious 
agents.9,21 It is the result of the acute phase response, a system-
wide process during which several proinflammatory cytok-
ines, such as tumor necrosis factor (TNF)-α, interleukin 
(IL)-1β, and IL-6, are released, primarily by macrophages.22 
These cytokines can enhance insulin resistance directly in 
adipocytes, muscle, and hepatic cells,23,24 leading to systemic 
disruption of insulin sensitivity and impaired glucose homeo-
stasis.25 Increased levels of proinflammatory cytokines lead to 
hepatic production and secretion of acute-phase proteins such 
as C-reactive protein (CRP), plasminogen activator inhibitor-1 
(PAI-1), amyloid-A, α1-acid glycoprotein, and haptoglobin. 
These proteins, collectively known as inflammatory   markers, 
appear in the early stages of T2D, and their circulating con-
centrations increase as the disease progresses.20,26
Chronic inflammation is closely associated with oxidative 
stress, an exaggerated presence of highly reactive molecular 
species, which leads to potential tissue damage.10,27 Oxidative 
stress results either from an increase in free radical produc-
tion, a decrease in endogenous antioxidant defenses, or 
both.5,28,29 Obesity and the metabolic syndrome, conditions 
which are considered key steps in the progression of insulin 
resistance to T2DM, are associated with both oxidative stress 
and inflammation.8,30,31 Hyperglycemia, increases in plasma 
levels of free fatty acids (FFAs), and hyperinsulinemia have 
all been linked to increased production of reactive oxygen 
species (ROS) and reactive nitrogen species (RNS).10,32–36 
ROS and RNS activate nuclear factor κB (NFκB), a proin-
flammatory transcription factor, that triggers a signalling 
cascade leading to a continued synthesis of oxidative species 
and the low-grade chronic inflammation.37–39
Given that obesity and the metabolic syndrome are steps 
toward the development of T2DM, their link with oxidative 
stress and inflammation points to a potential causative role for 
these factors in the progression of the disease.8 Thus, aiming 
to reduce oxidative imbalances and inflammation could lead 
to improved insulin sensitivity and delayed disease onset. 
Measures that prevent the development of oxidative stress 
and inflammation may present a feasible strategy for T2DM 
prevention and control. Dietary intake of micronutrients 
has been associated with reduced levels of oxidative stress, 
proinflammatory cytokines, and risk of T2DM in various 
cross-sectional and interventional studies,8,40–45 an approach 
that may facilitate the development of novel strategies for 
the prevention of T2DM.
This review was undertaken in an attempt to examine 
current knowledge linking micronutrients intake to oxidation 
and inflammatory signaling pathways in the pathogenesis of 
T2DM. The possibility that attenuating oxidative stress and 
inflammation by micronutrients can be employed as a novel 
approach for the prevention of T2DM is evaluated from the 
public health perspective.
Oxidative stress, inflammation,  
and T2DM
Oxidation is a chemical process whereby electrons are 
removed from molecules and highly reactive free radicals 
are generated.40 Free radicals include ROS such as superoxide 
and hydroperoxyl and RNS such as nitric oxide and nitrogen 
dioxide.5,10,17 Reactive species arise as natural by-products Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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of aerobic metabolism, and they play a role in numerous 
signaling cascades and physiological processes, such as 
phagocytosis, vasorelaxation, and neutrophil function.5,17,46,47 
However, excessive oxidation can trigger cytotoxic chain 
reactions that are damaging to membrane lipids, proteins, 
nucleic acids, and carbohydrates.17,27,46,48 Therefore, the 
capacity of serum to control production of free radicals is 
defined as the ‘total antioxidant status'.
The signaling transduction role of ROS stems from their 
ability to activate a number of stress-sensitive kinases whose 
downstream effects mediate insulin resistance.10 Activation of 
these kinases upregulates and activates NFκB and activator 
protein-1 (AP-1),49 which subsequently (a) activates c-Jun 
N-terminal kinase (JNK) and inhibitor of NFκB kinase-β 
(IKK), (b) transcriptionally upregulates proinflammatory 
cytokine genes,22 and (c) increases the synthesis of acute-
phase reactants.50–52 This molecular cascade reduces the 
downstream signaling elicited by insulin through dysregu-
lation of the insulin receptor (IR) substrate-1 (IRS-1), the 
primary molecular target of IR53,54 (Figure 2). Concurrently, 
the ensuing inflammation leads to an enhanced production 
of reactive oxidant species, further tipping the balance 
in favor of elevated oxidative stress and NFκB-mediated 
proinflammatory pathways.5,37,47 Because the JNK–AP-1 and 
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Figure  2  The  role  of  oxidative  stress  and  inflammation  in  insulin  resistance. 
A number of stimuli, such as hyperglycemia, high levels of circulating free fatty acid 
(FFA), and chronic inflammation, lead to increases in the production of reactive 
molecular species, and this in turn may lead to oxidative stress. Oxidants activate 
the JNK/AP-1 and iKK–NFκB axes, leading to an upregulation in the transcription 
of  proinflammatory  cytokine  genes  and  increased  production  of  cytokines  and 
acute-phase reactants. Cytokines impair the action of the insulin receptor substrate, 
resulting in impaired insulin action.
IKK–NFκB axes are the major inflammatory pathways that 
disrupt insulin signaling, modulating their action with anti-
oxidant or anti-inflammatory factors is believed to improve 
insulin sensitivity and glucose homeostasis.24
A number of studies have highlighted a direct link 
between oxidative stress and diabetes through the measure-
ment of markers of oxidative stress (eg, plasma and urinary 
F2-isoprostanes and plasma and tissue levels of nitrotyrosine 
and superoxide).17,55–59 Oxidative stress in diabetes arises 
from various pathways, including nonenzymatic, enzymatic, 
and mitochondrial processes. Hyperglycemia modifies the 
redox balance through the polyol pathway (where glucose 
is reduced to sorbitol, with subsequent decreases in levels 
of NADPH and reduced glutathione), activates oxidases, 
and interferes with the mitochondrial electron transport 
chain.35,60–63 These processes generate by-products that can 
trigger various signaling cascades, for example activation of 
protein kinase C to further increase the synthesis of reactive 
oxidative species.35,62,64 Nonenzymatically, glucose autoxi-
dation generates hydroxyl radicals65 and leads to the forma-
tion of advanced glycation end products that influence the 
transcription of proinflammatory genes to promote further 
oxidative stress.63,66 In healthy subjects, hyperglycemia has 
been also associated with oxidative stress, as measured 
through plasma levels of nitrotyrosine.67
Oxidative stress and chronic inflammation are closely linked 
via positive feedback mechanisms. Both factors are associated 
with obesity and a range of metabolic syndromes (Figure 3). 
High circulating FFA levels, which are characteristic of obesity 
and T2DM, influence oxidative stress via β-oxidative phos-
phorylation in mitochondria.5,6,35,38,62,68 In fact, plasma levels 
Oxidative stress Chronic inflammation
Obesity
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Figure 3 The interaction between oxidative stress, chronic inflammation, and the 
progression toward T2DM. Oxidative stress and chronic inflammation are closely 
linked via positive feedback mechanisms and are both associated with obesity and 
the metabolic syndrome.Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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insulin sensitivity,81 whereas inhibition of IKK by salicylates 
led to enhanced insulin action.82
The major current therapeutic agents to treat T2DM, 
sulfonylureas, metformin, and insulin-sensitizing glitazones, 
all have been associated with normalization of circulating 
inflammation and oxidative markers.12–14,83–85 This effect 
may be mediated, at least partly, by the action of the 
therapeutic agents on the innate immune system to retain 
the homeostasis of the oxidative and inflammatory status. 
Accordingly, glitazones (peroxisome proliferator-activated 
receptor-γ [PPAR-γ] agonists) improved the activities of 
superoxide dismutase and catalase and glutathione peroxidase 
in the lung tissue of hyperglycemic rabbits.12,86 Treatment of 
these animals with repaglinide, an antioxidant often used in 
T2DM treatment, resulted in higher glutathione levels and 
normalization of nitrotyrosine.83 Similarly, several thera-
peutic agents prescribed in T2DM, such as metformin and 
sulfonylureas, exhibit antioxidant and anti-inflammatory 
activity, an effect that may be partially related to their 
therapeutic efficacy.13,14,84,85 These observations provide an 
additional line of evidence to emphasize that targeting the 
inflammation-related and oxidation-related pathways can 
provide a feasible approach in the prevention of T2DM.
Micronutrient and/or trace element supplementation can 
modify oxidative stress and innate immune-related responses 
and, subsequently, reduce the burden of a range of chronic 
conditions. A recent study showed an interdependent and 
inverse association between total antioxidant capacity of the 
diet and CRP serum levels in nondiabetic subjects.87 This 
observation suggests the value of using nutritional supple-
mentation to modulate inflammation and oxidative stress in a 
population-based setting. With respect to T2DM, the consen-
sus of available information suggests that micronutrient intake 
modulates oxidative stress and the innate immune system88,89 
to subsequently influence the predisposition to (and prevention 
of) disease.88,90,91 Therefore, it is possible to monitor the out-
come of nutritional supplementation simply by evaluating its 
modifying action on the levels of inflammatory biomarkers.
Many micronutrients exhibit well-characterized anti-
inflammatory or immunomodulatory functions (see below). 
Vitamins (eg, D, E, and C) and trace elements (eg, Se, Zn, 
Cu, and Fe) are known to improve the overall function of the 
immune system, prevent excessive expression of inflamma-
tory cytokines, and increase the ‘oxidative burst’ potential 
of macrophages.88 Natural health products (NHPs) that 
contain pertinent micronutrients (eg, so-called adaptogenic 
medicinal plants) or modulate the innate immune response 
(eg, omega-3 fatty acids and probiotics) can also be explored 
of the antioxidant glutathione have been shown to decrease 
by FFA infusion.62,69 Furthermore, levels of malondialdehyde 
(MDA), a marker of oxidative stress, and expression of NFκB 
are elevated in insulin-resistant states when hyperglycemia is 
absent in vascular, adipose, and muscular tissues.62,69,70
Reactive species can play a role directly in insulin 
sensitivity, secretion, and action in both animal and human 
models.33,71–73 For example, nondiabetic rats that were infused 
with high levels of glucose and administered either of two 
antioxidants, that is, N-acetylcysteine or taurine, did not 
develop insulin resistance despite being hyperglycemic, 
suggesting that oxidative stress may play a role in glucose-
induced insulin resistance and that this effect can be pre-
vented by antioxidative factors.74 Oxidative stress has also 
been noted to coexist with insulin resistance in patients with 
T2DM,75,76 in obese subjects, and at various stages of the 
metabolic syndrome.10 For example, insulin resistance has 
been noted in obese women with reduced total antioxidant 
status30 and in men with plasma levels of 8-epi-prostaglandin 
F2α (PGF2α), a marker for lipid peroxidation.31 Furthermore, 
suboptimal concentrations of circulating antioxidants77 
and elevated levels of several markers of oxidative stress 
(eg, MDA, homocysteine, and ceruloplasmin) were found 
in subjects with metabolic syndrome.78
The effects of reactive oxidative species can be modified 
by enzymatic action (eg, superoxide dismutase, thioredoxin, 
catalase, and glutathione peroxidase)5 and/or by nonenzymatic 
antioxidants, for example, vitamins (A, C, E, and B), folate, 
glutathione, coenzyme Q10, α-lipoic acid (LA), carotenoids, 
flavonoids, and trace elements (Cu, Zn, Mg, and Se).17,79 
  Antioxidants often work in synergy with target specific reactive 
species,79 and through their ameliorating effects on oxidative 
stress, they also attenuate inflammation at the molecular level.
Micronutrients in T2DM: 
attenuation of oxidative  
stress and inflammation
Factors that attenuate oxidative stress and proinflammatory cas-
cades could provide an important public health tool to reduce 
the burden of chronic diseases linked to these conditions, such 
as obesity, T2DM, and cardiovascular diseases. A number 
of reports have evaluated the efficacy of anti-  inflammatory 
and antioxidant pharmaceutical agents on manifestation and 
outcome of T2DM and cardiovascular disease (see below). 
For example, studies in animal models and humans have dem-
onstrated that disrupting the IKKβ–NFκB pathway improves 
obesity-related insulin sensitivity.80 Blocking JNK activity in 
diabetic animals improved systemic glucose homeostasis and Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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for their preventive efficacy in chronic diseases despite their 
controversial benefits.92 Dietary intake of omega-3 fatty 
acids is known to inhibit the production of proinflammatory 
cytokines, including IL-1β and TNF-α.93 Furthermore, sup-
plementation with Allium sativum (garlic), Curcuma longa 
(long turmeric), Panax quinquefolius (American ginseng), 
and Panax ginseng (Asian ginseng), selected candidates of 
a large group of antioxidant, anti-inflammatory, and adap-
togenic plants, was reported to downregulate the oxidative 
stress and the synthesis of proinflammatory cytokines, effects 
related to their overall action on enhancing the innate immune 
response.94–98 Similarly, some trace elements (eg, Zn) could 
play a role in preventing T2DM by regulating dysglycemia 
and decreasing insulin insensitivity. For example, it is well 
known that T2DM can be accompanied by a slow loss of 
intracellular Zn and hyperzincuria.99 Supplementation with 
Zn, therefore, has been shown to lower oxidative stress-
related byproducts and to attenuate the synthesis of TNF-α 
and IL-1β.100–103 This observation may substantiate an antidi-
abetes action for Zn, and perhaps other trace elements, via its 
antioxidative and anti-inflammatory characteristics.
Exploring the possibility that supplementation with 
selected micronutrients, trace elements, and/or NHPs can 
attenuate inflammation and, subsequently, delay the onset of 
T2DM should be considered alongside existing public health 
practices to reduce the rising incidence of the disease. Here, 
we review the evidence for immunomodulatory, antioxidant, 
and anti-inflammatory effects of specific micronutrients, 
namely vitamins D, C, and E, and their overall effect on the 
prevention of T2DM and the related metabolic syndromes.
vitamin D
The role of vitamin D in calcium and phosphorous homeostasis 
and bone metabolism is well understood. However, more 
recently, vitamin D and calcium homeostasis have also been 
linked to a number of conditions, such as neuromuscular 
function, cancer, and a wide range of chronic diseases, 
including autoimmune diseases, atherosclerosis, obesity, 
cardiovascular diseases, diabetes, and associated conditions 
such as the metabolic syndrome and insulin resistance.8,91,104,105 
In T2DM, the role of vitamin D was suggested from the pres-
ence of vitamin D receptors (VDR) in the pancreatic β-islet 
cells.106 In these cells, the biologically active metabolite of 
vitamin D (ie, 1,25-dihydroxy-vitamin D; 1,25(OH)2D)88 
enhances insulin production and secretion via its action 
on the VDR.106 Indeed, the presence of vitamin D binding 
protein (DBP), a major predictor of serum levels of 25(OH)
D and response to vitamin D supplementation,107,108 and VDR 
initiated several studies demonstrating a relationship between 
single-nucleotide polymorphisms (SNPs) in the genes regu-
lating VDR and DBP and glucose intolerance and insulin 
secretion.109–111 This further supports a role for vitamin D in 
T2DM and may explain the reduced overall risk of the dis-
ease in subjects who ingest .800 IU/day of vitamin D.91,112 
However, an alternative, perhaps related, explanation was 
recently proposed for the role of vitamin D in the prevention of 
T2DM based on its potent immunomodulatory functions.113–115 
1,25(OH)2D modulates the production of the immunostimula-
tory IL-12 and the immunosuppressive IL-10,116 and VDRs 
are present in most types of immune cells.117 In this respect, 
supplementation with vitamin D118 or its bioactive form, 
1,25(OH)2D,88 improved insulin sensitivity by preventing the 
excessive synthesis of inflammatory cytokines. This effect of 
vitamin D on cytokine synthesis is due to its interaction with 
vitamin D response elements present in the promoter region 
of cytokine-encoding genes. This interaction downregulates 
the transcriptional activities of cytokine genes and attenuates 
the synthesis of the corresponding proteins.118 Vitamin D also 
deactivates NFκB, which transcriptionally regulates the proin-
flammatory cytokine-encoding genes.119 Downregulating the 
expression of NFκB and downstream cytokine genes inhibits 
β-cell apoptosis and promotes their survival.118
As reviewed by Pittas et al,91,120 a number of cross-
sectional studies in both healthy and diabetic cohorts have 
shown an inverse association between serum 25(OH)D and 
glycemic status measures such as fasting plasma glucose, oral 
glucose tolerance tests, hemoglobin A1c (HbA1c), and insulin 
resistance as measured by the homeostatic model assess-
ment (HOMA-R), as well as the metabolic syndrome.3,121–125 
For example, data from the National Health and Nutrition 
Examination Survey showed an inverse, dose-dependent 
association between serum 25(OH)D and diabetes prevalence 
in non-Hispanic whites and Mexican Americans, but not 
in non-Hispanic blacks.122,125 The same inverse trend was 
observed between serum 25(OH)D and insulin resistance as 
measured by HOMA-R, but there was no correlation between 
serum levels of vitamin D and β-cell function, as measured 
by HOMA-β.122,125 Data from the same cohort also showed an 
inverse association between serum 25(OH)D and prevalence 
of the metabolic syndrome.122
In prospective studies, dietary vitamin D intake has been 
associated with incidence of T2DM. For example, data from the 
Women’s Health Study showed that among middle-aged and 
older women, taking .511 IU/day of vitamin D reduced the 
risk of developing T2DM compared to ingesting 159 IU/day.126 
Furthermore, data from the Nurses Health Study also found a Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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significant inverse correlation between total vitamin D intake 
and T2DM risk, even after adjusting for BMI, age, and nondi-
etary covariates.112 Intervention studies have shown conflict-
ing results about the effect of vitamin D on T2DM incidence. 
One study reported that supplementation with 1,25(OH)2D for 
1 week did not affect fasting glucose or insulin sensitivity in 
18 young, healthy men.127 Another study found that among 14 
T2DM patients, supplementing with 80 IU/day of 1,25(OH)2D 
ameliorated insulin secretion but did not improve glucose 
  tolerance after a 75-g oral load.128 Yet another study showed that 
among 65 middle-aged men who had IGT or mild T2DM and 
adequate serum vitamin D levels at baseline, supplementation 
with 30 IU/day of 1,25(OH)2D for 3 months affected neither 
fasting nor stimulated glucose tolerance.129 However, in a 
crossover design, 20 diabetics with inadequate vitamin D serum 
levels who were given 40 IU/day of 1,25(OH)2D for 4 days had 
improved insulin secretion, but showed no changes in fasting 
or stimulated glucose or insulin concentrations.130 Although the 
short duration of this crossover trial may account for the lack 
of a significant overall effect, the results suggest that improv-
ing vitamin D status can modulate factors associated with the 
development and progression of T2DM.
The data from a 2-year-long trial designed to assess the 
effects of vitamin D or 1,25(OH)2D supplementation on bone 
health in nondiabetic postmenopausal women were analyzed 
a posteriori and found no significant effect on fasting glucose 
levels.131 A post hoc analysis of data from a 3-year-long trial for 
bone health showed that daily supplementation with 700 IU of 
vitamin D3 and 500 mg of calcium citrate malate did not change 
blood glucose levels or insulin resistance in elderly adults with 
normal glucose tolerance. These measures, however, were sig-
nificantly improved in subjects with IGT at baseline.90 In this 
trial, the effect of fasting glucose levels in the high-risk group 
(ie, IGT) was similar to that observed in the Diabetes Prevention 
Program after either an intensive lifestyle intervention or met-
formin treatment.132 Another recent randomized, controlled trial 
found that daily supplementation with 400 IU of vitamin D3 for 
6 months in insulin-resistant, nondiabetic, vitamin D-deficient 
South Asian women living in New Zealand resulted in improved 
insulin resistance and sensitivity.133 Taken together, the available 
information warrants exploring the possibility that vitamin D, 
either alone or in combination with calcium supplementation, 
can be employed in developing population-based strategies for 
T2DM prevention and control.
vitamin C
Vitamin C (ascorbic acid or ascorbate) is the primary 
hydrophilic antioxidant found in human plasma.134 
Absorption of vitamin C occurs in the small intestine via 
active transport through the sodium-dependent vitamin C 
transporter type 1 (SVCT1). SVCT1 also appears in the renal 
proximal tubules, where it reabsorbs filtered ascorbate and is 
expressed throughout the body.135 Circulating concentrations 
of ascorbate in blood are considered adequate if it is at least 
28 µM, but they are considerably higher in most cells due to 
active transport by SVCT2. The daily recommended dietary 
allowance for vitamin C is 75 mg for women and 90 mg for 
men, with an additional 35 mg for smokers due to the higher 
metabolic turnover of the vitamin in this group compared to 
nonsmokers.37 Ascorbate appears in the urine at intakes of 
roughly 60 mg/day. However, in a depletion/repletion study in 
healthy young women, ascorbate plasma and white blood cell 
concentrations saturated at intakes of 200 mg/day or higher.136 
These results suggest that for some individuals, the current 
dietary recommendations may not provide tissue-saturating 
ascorbate concentrations.135 Recent epidemiologic findings 
suggest that serum ascorbic acid deficiency may be relatively 
common. For example, a recent cross-sectional survey of 
healthy young adults of the Toronto Nutrigenomics and Health 
(TNH) Study reported that one out of seven individuals is 
deficient in serum ascorbic acid.137
Vitamin C has an important role in immune function and 
various oxidative/inflammatory processes, such as scavenging 
ROS and RNS, preventing the initiation of chain reactions 
that lead to protein glycation,37,40 and protecting against 
lipid peroxidation.37,138 The oxidized products of vitamin C, 
ascorbyl radical and dehydroascorbic acid, are easily regener-
ated to ascorbic acid by glutathione, NADH, or NADPH.37 
In addition, ascorbate can recycle vitamin E and glutathione 
back from their oxidized forms.37,135 For this reason, there 
has been interest in determining whether vitamin C might be 
used as a therapeutic agent against the oxidative stress and 
subsequent inflammation associated with T2DM.
A variety of epidemiologic studies have assessed the 
effect of vitamin C on biomarkers of oxidation, inflammation, 
and/or T2DM risk.134,139–144 A large cross-sectional evalua-
tion of healthy elderly men from the British Regional Heart 
Study reported that plasma vitamin C, dietary vitamin C, 
and fruit intake were inversely correlated with serum CRP 
and tissue plasminogen activator (tPA), a biomarker of 
endothelial dysfunction.134 However, only plasma vitamin C 
was inversely associated with fibrinogen levels.134 Another 
cross-sectional study of adolescents aged 13–17 found 
inverse associations between intake of fruit, vegetables, 
legumes, and vitamin C and urinary F2-isoprostane, CRP, 
and IL-6.145 A recent cross-sectional evaluation of healthy Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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young adults from the TNH Study demonstrated that serum 
ascorbic acid deficiency is associated with elevated CRP 
and other factors related to the metabolic syndrome such as 
waist circumference, BMI, and blood pressure.137 Finally, 
the European Prospective Investigation of Cancer-Norfolk 
Prospective Study examined the association between fruit 
and vegetable intake and plasma levels of vitamin C and risk 
of T2DM. During a 12-year follow-up, 735 incident cases of 
diabetes were identified among nearly 21,000   participants. 
A significant inverse association was found between 
plasma levels of vitamin C and risk of diabetes (odds ratio 
[OR] = 0.38, 95% confidence interval [CI]: 0.28–0.52). In 
the same study, a similar association was observed between 
fruit and vegetable intake and T2DM risk (OR = 0.78, 95% 
CI: 0.60–1.00).41
Despite epidemiologic findings generally pointing toward 
an association between increased vitamin C and reduced 
oxidation and inflammation, intervention trials assessing the 
effect of vitamin C supplementation on various markers of 
T2DM have yielded inconsistent results. One randomized, 
crossover, double-blind intervention trial reported no 
improvement in fasting plasma glucose and no significant 
differences in levels of CRP, IL-6, IL-1 receptor agonist, or 
oxidized low-density lipoprotein (LDL) after supplementa-
tion with 3000 mg/day of vitamin C for 2 weeks in a group of 
20 T2DM patients, compared to baseline levels.146 Chen and 
colleagues performed a randomized, controlled, double-blind 
intervention on a group of 32 diabetic subjects with inadequate 
levels of vitamin C and found no significant changes in either 
fasting glucose or fasting insulin after intake of 800 mg/day 
of vitamin C for 4 weeks.147 Furthermore, Tousoulis et al 
reported that treatment with 2000 mg/day for 4 weeks had 
no effect on levels of CRP, IL-6, TNF-α, or soluble vascular 
cell adhesion molecule-1 in 13 T2DM patients.148
On the other hand, Wang and colleagues showed that the 
red blood cell sorbitol/plasma glucose ratio was reduced after 
supplementation with 1000 mg/day vitamin C for 2 weeks in a 
group of eight diabetics, although no differences were found in 
fasting plasma glucose.42 Because sorbitol is a product of the 
pro-oxidative polyol pathway, this observation may suggest an 
inhibition of the polyol pathway by vitamin C among subjects 
with diabetes. Another study has shown that daily intake of 
ascorbic acid at 2000 mg/day improved fasting plasma glucose, 
HbA1c, cholesterol levels, and triglycerides in 56 diabetics.149 
In agreement, Paolisso et al found that 1000 mg/day of vitamin 
C for 4 months improved LDL and total cholesterol, fasting 
plasma insulin, and free radicals, although it did not affect 
triglycerides or HDL levels in a group of 40 diabetics.43
Overall, it remains unclear whether vitamin C intake 
has an effect on factors related to T2DM. Although the 
epidemiologic evidence suggests that vitamin C, whether as 
a supplement or as part of a diet rich in fruits and vegetables, 
beneficially affects inflammatory markers and disease risk, 
the results of intervention trials in T2DM are conflicting. 
Small sample sizes, genetic variation, short intervention dura-
tion, insufficient dosage, and disease status of the assessed 
cohorts may account for the lack of effect and the inconsistent 
outcomes observed in intervention studies. However, it is also 
possible that the status of vitamin C deficiency is a result of 
the oxidative and proinflammatory challenges associated with 
T2DM, rather than a determinant of disease pathogenesis. 
Therefore, further research and long-term prospective studies 
are needed to elucidate the role of vitamin C as a modulator 
of inflammation and T2DM risk and to evaluate its potential 
role as a preventive agent at a population level.
vitamin e
Vitamin E occurs as four common types: α tocopherol, 
β tocopherol, γ tocopherol, and δ tocopherol, and these 
differences in chemical structure have different molecular 
functions and impacts.40 α Tocopherol is the major form 
recognized by the α tocopherol transfer protein in the 
liver and is, therefore, incorporated into very low-density 
lipoprotein, whereas γ tocopherol is metabolized and thus 
not retained. This results in much higher concentrations 
of α than γ tocopherol in the body.37 Although vitamin E 
supplements consist primarily of α tocopherol, γ tocopherol 
is the main dietary source of the vitamin, as it is found in 
various vegetable oils, seeds, and nuts.37 Vitamin E intake 
increases the rate of lymphocyte proliferation by enhancing 
the ability of T cells to undergo cell division cycles.150 Its 
anti-inflammatory action, however, has been substantiated 
from observations demonstrating its ability to modulate the 
expression of the IL-2 and IL-4 genes and the IL-1 receptor 
antagonist following supplementation in animal models.151 
In T2DM patients, vitamin E reduced the serum levels of 
IL-1β, IL-6, TNF-α, PAI-1, and CRP.15
The anti-inflammatory actions of vitamin E are believed 
to be related to its post-transcriptional inhibitory action on 
5-lipoxygenase,152 a member of the lipoxygenase family 
of enzymes involved in the synthesis of the inflammatory 
prostaglandins. Additionally, vitamin E downregulates 
NFκB and exerts potent lipophilic antioxidant effect on 
internal and external cell membranes as well as plasma 
lipoproteins, notably LDL.15 Indeed, studies in both animal 
models and humans have demonstrated that vitamin E Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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intake blocks LDL lipid peroxidation, prevents the oxidative 
stress linked to T2DM-associated abnormal metabolic 
patterns (hyperglycemia, dyslipidemia, and elevated levels 
of FFAs), and, subsequently, attenuates cytokine gene 
expression.15,62,151,153
A number of epidemiological studies demonstrated 
an inverse association between vitamin E and markers of 
oxidation, inflammation, and T2DM incidence.154–156 For 
example, a 4-year prospective assessment of 944 nondia-
betic Finnish men found that below-median plasma vitamin 
E levels were associated with a 3.9-fold higher relative risk 
of diabetes (95% CI: 1.8–8.6).154 Another case-control study 
(n = 106 cases, 201 controls) reported an inverse association 
between vitamin E serum levels and T2DM status, 
although the association became statistically insignificant 
after adjusting for cardiovascular disease risk factors (ie, 
serum cholesterol, obesity, smoking, and hypertension).155 
The Insulin Resistance Atherosclerosis Study, a 5-year 
prospective study of nearly 900 nondiabetic adults, found 
that plasma concentrations of α tocopherol offered a 
significant protective effect against T2DM (OR = 0.12, 95% 
CI: 0.02–0.68).156 In contrast, various epidemiologic studies 
and intervention trials (see below) reported inconsistent 
findings. For example, supplementation with 750 IU/day 
of mixed tocopherols for 6 weeks reduced plasma but not 
urinary F2-isoprostanes, a marker of oxidative stress in 
vivo, in two different studies on subjects with T2DM.157,158 
This level of supplementation did not alter the serum 
concentration of CRP, IL-6, TNF-α, or MCP-1 in one 
study158 and was associated with increased blood pressure 
and heart rate in another trial.157
Data from the Women’s Health Study, assessing women 
health at baseline, demonstrated that supplementation with 
600 IU of α tocopherol for 10 years on alternate days had 
no significant benefit for T2DM.159 However, in another 
trial of 15 diabetics and 10 control individuals, 4 months of 
daily supplementation with 1350 IU of α tocopherol signifi-
cantly improved plasma glucose levels, triglycerides, total 
cholesterol levels, LDL, and HbA1c, but did not improve the 
response of β cells to glucose or FFAs.44 In a trial involving 
34 Mexican diabetic women, daily supplementation with 
800 IU of α tocopherol for 6 weeks improved total antioxidant 
status and reduced MDA levels, but had no effect on serum 
glucose, lipids, or HbA1c levels.160 Daily supplementation 
with 1600 IU of α tocopherol for 10 weeks in a group of 21 
diabetic men had no effect on HbA1c, fasting blood glucose, or 
glycated plasma protein concentrations, but had a beneficial 
effect on LDL oxidation.161
Despite these conflicting findings, a recent study 
evaluated the effects of daily supplementation of a combina-
tion of vitamin C (20,000 IU) and vitamin E (400 IU) for 
4 weeks on insulin sensitivity in untrained (n = 19) and trained 
(n = 20) healthy young men.162 The study concluded that such 
a regimen may preclude the exercise-induced amelioration 
of insulin resistance in humans.162 This may relate to the 
source of vitamin E used, that is, α, β, γ, or δ tocopherols.163 
Indeed, one study assessed the differences between α and γ 
tocopherols on factors related to the metabolic syndrome.164 
Subjects with the metabolic syndrome were administered 
either form of vitamin E or an equal mixture of the two 
at doses of 1200 IU/day for 6 weeks. Plasma levels of 
IL-1β, TNF-α, IL-6, CRP, and markers of oxidative stress 
were measured. Serum levels of CRP were decreased after 
supplementation with both α and γ tocopherols, and only 
the combined treatment yielded a significant lowering effect 
on the inflammatory markers. TNF-α decreased with α and 
mixed tocopherols, but neither IL-1β nor IL-6 were affected 
by any treatment regimen. Markers of oxidative stress, such 
as MDA and lipid peroxides, were significantly reduced with 
all treatments.164 These results suggest that supplementation 
with combined α and γ tocopherols may be more beneficial 
in reducing oxidative stress and inflammation than either 
isoform alone. Furthermore, given the role of vitamin C in 
regeneration of oxidized vitamin E (see above), combined 
vitamin C and vitamin E may be more effective than admin-
istering either micronutrient on its own. For example, 13 
elderly men with impaired fasting glucose were given a daily 
combination of 1000 mg α tocopherol and 1000 IU vitamin 
C for 4 weeks. The combined supplement yielded signifi-
cant reductions in levels of fasting plasma insulin, glucose, 
TNF-α, and 8-isoprostane.45
In general, inconsistent results from studies evaluat-
ing the effect of vitamin E on inflammation, oxidation, 
and T2DM risk may result partly from genetic differences 
between individuals that could lead to variations in response 
to micronutrient exposure. For example, SNPs in the TNF-α 
gene (eg, −308 G.A) affected the inflammatory response of 
elderly individuals to supplementation with 273 IU/day of α 
tocopherol for 1 year.165 When carriers of the A allele received 
vitamin E, they had lower TNF-α synthesis upon exposure 
to lipopolysaccharides compared to their nonsupplemented 
counterparts. Because the A allele has been previously asso-
ciated with higher TNF-α levels, it was concluded that the 
anti-inflammatory effects of vitamin E are specific to those 
who are genetically predisposed to develop inflammatory 
responses upon exposure to stimuli.165 This observation is Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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critical in identifying subjects of the general population who 
will benefit more from vitamin E supplementation based on 
their genetic predisposition to disease-related factors.
Conclusion and future directions
Introducing novel and effective prevention strategies in a 
public health setting necessitates considering approaches with 
the least (if any) side effects and the maximal preventive effi-
cacy and outcome. In this context, applying nutritional inter-
vention to attenuate inflammation and oxidative stress would 
be a feasible public health strategy for prevention of T2DM. 
This approach should be explored in prediabetic subjects and 
the outcome should be compared to the effect(s) of modifying 
current practices, such as lifestyle change, dietary interven-
tion, and exercise. The effectiveness of lifestyle-change 
intervention programs for prediabetes also shows a promising 
effect on the reduction of overall incidence of T2DM or its 
complications, and it can be implemented in general clinical 
practice.166 A lifestyle-change program including increased 
exercise and change in diet (either by reduction in glycemic 
load or reduced-fat diet) demonstrated a significant differ-
ence between control and intervention groups in markers for 
risk of progression to T2DM including weight, BMI, and 
waist circumference.166 In general, current approaches for 
the prevention of T2DM have been shown to be effective in 
delaying or preventing the progression from prediabetes to 
diabetes.167 In patients with insulin resistance, these practices 
are known to improve insulin sensitivity and the overall 
predisposition to T2DM.168 On the other hand, increasing 
intake of vitamin D to .800 IU daily along with 1200 mg of 
calcium was reported to reduce the risk of developing T2DM 
by 33%.91 In agreement, healthy older adults with impaired 
fasting glucose showed significant improvement in attenuat-
ing the glycemic response and insulin resistance when they 
increased their intake of vitamin D by 700 IU/day and calcium 
by 500 mg/day for 3 years.112
It seems reasonable, therefore, to suggest that the two 
preventive approaches for T2DM, that is micronutrient 
supplementation and lifestyle change, may be combined into 
a single successful intervention program. This strategy may 
be more efficient in reducing the burden of the disease in the 
general population and in vulnerable subpopulations than 
when a single approach is proposed. Moreover, such a com-
bined approach may be introduced into the general practice 
setting and to the general population with low expenditure 
and minimal side effects.8
Overall, the current state of knowledge warrants further 
study into the extent to which micronutrients can modify the 
association between markers of inflammation and oxidative 
stress and early stages of T2DM. There is evidence supporting 
the idea that vitamin supplementation can modify the 
genotype–phenotype association within the innate immune 
response (ie, the proinflammatory and inflammatory markers) 
and that it has an ameliorating effect on oxidative stress and 
the subsequent proinflammatory signaling. This proposition 
may provide the mechanism by which nutritional factors pre-
vent or delay disease development and can be introduced into 
the general population, as well as susceptible subpopulations. 
In relation to the current preventive approaches for T2DM, 
for example, lifestyle changes, exercise, and dietary interven-
tion, exploring the efficacy of micronutrient supplementation 
on attenuating oxidative stress, the innate immune response, 
and the ensuing inflammation and evaluating the outcome of 
this strategy on T2DM incidence may be assessed through 
a series of prospective population-based studies, first, to 
determine the feasibility and effectiveness of this protocol; 
second, to validate and evaluate this strategy and ensure 
replication of results; and, third, to monitor the outcome to 
quantify the overall preventive response in comparison with 
the current approaches. As reviewed by Willcox et al,169 study 
design is an issue to consider when assessing the efficacy of 
antioxidants in reducing the risk of developing cardiometa-
bolic diseases. Intervention trials should be designed with 
sufficient power to measure T2DM as a primary, rather than 
a secondary, outcome. Furthermore, these studies should 
investigate the effects of antioxidant vitamins and trace ele-
ments in representative populations so that the results are 
applicable to high-risk groups, and they should take into 
account genetic variation accounting for interindividual 
differences in response to supplementation. Consideration 
should be also given to the antioxidants given in specific 
studies, as different antioxidants exert their effects through 
different mechanisms.169
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